These findings all suggested that our melanoma patients might be with more primary resistance to immunotherapy, due to worse immune microenvironment, less PD‐L1 expression, lower tumor mutation burden (TMB), and different drug resistance mechanisms.21, 22, 23. Here, CD274 is linked to melanoma.